Biogen Inc
NASDAQ:BIIB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
155.43
267.71
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIIB stock under the Base Case scenario is 202.048 USD. Compared to the current market price of 158.605 USD, Biogen Inc is Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biogen Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIIB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Biogen Inc. is a renowned biotechnology company that has carved out a niche in the development and delivery of groundbreaking therapies for neurological diseases. Founded in 1978, the company has focused on addressing some of the most challenging and complex health conditions, particularly multiple sclerosis (MS) and Alzheimer’s disease. With a robust pipeline of innovative treatments, Biogen aims to improve the lives of individuals affected by debilitating neurological disorders. Its flagship products, including drugs such as Tecfidera and Avonex, have notably solidified Biogen's reputation as a leader in MS treatment, contributing significantly to its revenue stream and positioning the com...
Biogen Inc. is a renowned biotechnology company that has carved out a niche in the development and delivery of groundbreaking therapies for neurological diseases. Founded in 1978, the company has focused on addressing some of the most challenging and complex health conditions, particularly multiple sclerosis (MS) and Alzheimer’s disease. With a robust pipeline of innovative treatments, Biogen aims to improve the lives of individuals affected by debilitating neurological disorders. Its flagship products, including drugs such as Tecfidera and Avonex, have notably solidified Biogen's reputation as a leader in MS treatment, contributing significantly to its revenue stream and positioning the company as a pivotal player in the biopharmaceutical landscape.
In recent years, Biogen has expanded its focus to tackle Alzheimer’s disease, with the controversial introduction of Aduhelm, the first new Alzheimer’s treatment in nearly two decades. This move has drawn both attention and scrutiny from investors and healthcare professionals alike, highlighting the intense debates around pricing, efficacy, and regulatory oversight in the biotech sector. As Biogen continues to innovate, it is also making strides in strategic partnerships and collaborations to enhance its research capabilities and broaden its therapeutic offerings. With a strong commitment to enhancing patient outcomes and a growing reputation for scientific excellence, Biogen presents a compelling investment opportunity, albeit with the inherent risks associated with the dynamic and rapidly evolving field of biotechnology.
Biogen Inc. is a biotechnology company that primarily focuses on discovering, developing, and delivering innovative treatments for neurological diseases. The core business segments of Biogen can be categorized as follows:
-
Multiple Sclerosis (MS): Biogen is a leader in the treatment of MS, offering several therapies that are aimed at reducing the frequency of relapses and slowing the progression of the disease. Key products in this segment include Avonex, Tysabri, and Tecfidera.
-
Neuromuscular Disorders: This segment focuses on therapies for conditions such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). Notable products include Spinraza for SMA and the recently developed therapies targeted at ALS.
-
Neurodegenerative Diseases: Biogen is engaged in developing treatments for various neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. The company has made significant investments in research and development in this area, with Aducanumab (Aduhelm) being one of the most discussed products related to Alzheimer’s.
-
Immunology: This segment includes therapies that address autoimmune conditions. While Biogen primarily focuses on neurological disorders, its immunology pipeline is expanding, looking into various treatment avenues in this space.
-
Biosimilars: Biogen is also involved in the biosimilars market, offering biologic products that mimic the efficacy and safety of already approved reference products, thus contributing to more affordable treatment options in the biotechnology space.
-
Research and Development: Supporting all these segments is Biogen's extensive investment in R&D. This encompasses developing new therapies, advancing clinical studies, and exploring innovative treatment modalities, including gene therapy and potential new indications for existing products.
Biogen’s business model is characterized by its commitment to innovation and a robust pipeline aimed at addressing unmet medical needs, particularly in the neurological landscape. The company strategically invests in research collaborations and partnerships to enhance its portfolio and bring new therapies to market.
Biogen Inc., a leader in the biotechnology sector, particularly in neurology, has several unique competitive advantages over its rivals:
-
Strong Portfolio of Proprietary Drugs: Biogen has developed a robust portfolio of proprietary treatments, particularly in the field of multiple sclerosis (MS) and spinal muscular atrophy (SMA). Its well-established drugs like Avonex, Tysabri, and Spinraza provide a significant revenue base and a reputation for innovation.
-
Expertise in Neuroscience: Biogen has a long-standing focus on neurological diseases, allowing it to gain deep expertise and insights into this complex field. This specialization fosters innovation and can lead to breakthroughs that competitors may not achieve.
-
Robust R&D Pipeline: The company invests heavily in research and development, continually working on new therapies and indications. Their pipeline includes promising candidates for Alzheimer’s disease, other neurodegenerative conditions, and neurological disorders, offering the potential for future growth.
-
Strategic Collaborations and Partnerships: Biogen has formed strategic collaborations with other biotech and pharmaceutical companies, enhancing its research capabilities and expanding its reach into new technologies, such as gene therapy and monoclonal antibodies.
-
Strong Intellectual Property Portfolio: The company has a well-protected portfolio of patents surrounding its drugs and research technologies, providing a competitive moat against generic competition and potential infringement.
-
Global Presence and Distribution Network: Biogen has a well-established global distribution network that enables it to reach diverse markets efficiently. This global presence helps in mitigating risks associated with specific geographical dependence.
-
Experienced Management Team: The leadership team comprises seasoned professionals with extensive industry experience, fostering a culture of strategic decision-making and operational excellence.
-
Focus on Patient-Centricity: Biogen places a strong emphasis on improving patient outcomes and enhancing the quality of life through its therapies. This patient-centric approach aids in maintaining customer loyalty and brand strength.
-
Significant Market Share in Core Areas: Biogen holds a significant market share in its core therapeutic areas, giving it leverage in pricing and negotiation with healthcare providers and insurers.
-
Commitment to Sustainability and Corporate Social Responsibility: As the emphasis on sustainability and ethical practices grows, Biogen’s commitment to these areas can enhance its public image and establish stronger relationships with stakeholders.
These competitive advantages position Biogen favorably against its rivals and enhance its long-term growth prospects in the biopharmaceutical industry.
Biogen Inc., as a leading biotechnology company, faces several risks and challenges in the near future:
-
Regulatory Scrutiny: Biogen's products, especially its high-profile drugs like Aduhelm for Alzheimer's, have faced significant regulatory scrutiny. Any future drugs will likely be subject to rigorous evaluation, and negative outcomes can impact approval timelines and revenue potential.
-
Market Competition: The biopharmaceutical industry is highly competitive. Biogen faces competition from both established companies and emerging biotech firms. Innovations in treatment options for neurological disorders could overshadow Biogen's existing products.
-
Market Access and Pricing Pressure: As healthcare costs rise, there is increasing pressure on drug pricing. Payers and healthcare providers may resist high prices for Biogen's treatments, leading to reduced market access and lower sales volumes.
-
Innovation and R&D Pipeline: Biogen must continuously innovate to maintain its market position. Delays or failures in clinical trials could hinder the development of new therapies. The loss of patent exclusivity on existing products could also affect revenue.
-
Reputational Risks: Controversies related to clinical trials, pricing practices, or product efficacy can harm Biogen’s reputation. Negative public perception can also lead to legislative pressures and changes in healthcare policy.
-
Intellectual Property Issues: Protecting intellectual property is critical for biotech firms. Patent challenges or expirations could impact Biogen’s ability to maintain competitive advantages in its product lines.
-
Economic Factors: Broader economic conditions, such as recessions or shifts in healthcare funding can impact Biogen's sales and profitability. Changes in regulatory policies at the federal level could also affect market dynamics.
-
Global Operations and Supply Chain: Any disruptions in global supply chains, whether due to geopolitical issues, pandemics, or natural disasters, could impact Biogen’s ability to manufacture and distribute its products effectively.
-
Talent Retention and Recruitment: The biopharmaceutical industry relies on highly skilled professionals. Attracting and retaining top talent is essential for research and development, and any challenges in this area may hinder progress.
-
Healthcare Trends and Patient Needs: Rapid changes in patient demographics and healthcare accessibility can influence Biogen’s business strategy. Adapting to these shifts and ensuring alignment with patient and healthcare provider needs is crucial.
In summary, while Biogen holds a strong position in the biotech landscape, navigating these multifaceted risks will be essential for its sustained growth and shareholder value creation.
Revenue & Expenses Breakdown
Biogen Inc
Balance Sheet Decomposition
Biogen Inc
Current Assets | 6.8B |
Cash & Short-Term Investments | 1.7B |
Receivables | 2B |
Other Current Assets | 3.1B |
Non-Current Assets | 21.5B |
Long-Term Investments | 631.4m |
PP&E | 3.6B |
Intangibles | 16.3B |
Other Non-Current Assets | 968.7m |
Current Liabilities | 5.4B |
Accounts Payable | 422.7m |
Accrued Liabilities | 1.7B |
Other Current Liabilities | 3.3B |
Non-Current Liabilities | 6.5B |
Long-Term Debt | 4.5B |
Other Non-Current Liabilities | 2B |
Earnings Waterfall
Biogen Inc
Revenue
|
9.6B
USD
|
Cost of Revenue
|
-2.3B
USD
|
Gross Profit
|
7.3B
USD
|
Operating Expenses
|
-4.8B
USD
|
Operating Income
|
2.5B
USD
|
Other Expenses
|
-875.5m
USD
|
Net Income
|
1.6B
USD
|
Free Cash Flow Analysis
Biogen Inc
USD | |
Free Cash Flow | USD |
In the third quarter, Biogen reported $2.5 billion in revenue, reflecting a 3% decline year-over-year. Despite challenges in the MS product line, non-GAAP operating income rose by 4%. The company raised its 2024 non-GAAP EPS guidance to $16.10-$16.60, indicating a projected growth of about 11% from the previous year. Notably, rare disease revenues grew 10% to $495 million, driven by strong demand for SKYCLARYS, while ZURZUVAE saw a 49% increase in revenue. The anticipated rollout of subcutaneous formulations and stronger sales strategies may bolster future growth. The financial health remains solid with $1.7 billion in cash and a focus on sustainable growth strategies.
What is Earnings Call?
BIIB Profitability Score
Profitability Due Diligence
Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Biogen Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BIIB Solvency Score
Solvency Due Diligence
Biogen Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Biogen Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for BIIB is 253.572 USD with a low forecast of 181.8 USD and a high forecast of 359.1 USD.
Dividends
Current shareholder yield for BIIB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BIIB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 9,610 full-time employees. The company is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Contact
IPO
Employees
Officers
The intrinsic value of one BIIB stock under the Base Case scenario is 202.048 USD.
Compared to the current market price of 158.605 USD, Biogen Inc is Undervalued by 22%.